ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

Core Insights - ARS Pharmaceuticals reported preliminary fourth quarter neffy net product revenue of approximately $6.5 million, with total net product sales for 2024 reaching approximately$7.1 million since the product's launch on September 23, 2024 [4] - The company has a strong cash position, with cash, cash equivalents, and short-term investments totaling approximately $314.0 million as of December 31, 2024, which is expected to support operations for at least three years [4] - The company aims to enhance neffy sales in 2025 through targeted commercial initiatives, including increasing education and awareness among prescribers and launching direct-to-consumer marketing campaigns [3][4] Financial Performance - Preliminary neffy net product revenue for Q4 2024 was approximately$6.5 million, with over 14,500 two-pack units delivered in the quarter [4] - Total net product sales for 2024 amounted to approximately $7.1 million since the product became available [4] - The company anticipates achieving over 80% commercial insurance coverage by the end of Q3 2025 [4] Strategic Initiatives - The company plans to expand its neffy Experience Program and increase engagement with healthcare providers, with over 3,000 providers having prescribed neffy to date [4] - A branded direct-to-consumer marketing campaign is set to launch in May 2025, aimed at building brand recognition ahead of the back-to-school season [4][11] - The company is on track to secure more than 60% commercial coverage by the end of Q1 2025 [4] Upcoming Events - Richard Lowenthal, President and CEO of ARS Pharmaceuticals, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [5]